Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified?
- PMID: 16079326
- DOI: 10.1093/ndt/gfh1109
Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified?
Abstract
Resistance to erythropoiesis-stimulating agents (ESA) in patients with chronic kidney disease (CKD) can be associated with evidence of enhanced systemic inflammatory responses. This review considers the inflammatory mechanisms thought to be involved in the development and aetiology of anaemia of CKD that may help our understanding and management of patients with ESA resistance. The potential role of nutritional support and of anti-inflammatory therapies in managing resistance to ESA therapy is discussed and explored.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical